Sponsored by
We are proud to announce that we have awarded a new $50,000 venture philanthropy grant to AVIL Therapeutics to support promising research aimed at developing a targeted therapy for glioblastoma (GBM). Our venture philanthropy model helps accelerate research projects that show both scientific rigor and clear potential for patient benefit. By supporting early-stage but transformative ideas, we help bridge the gap between discovery and future clinical trials.
This grant supports preclinical work focused on AVIL (advillin), a newly identified cancer driver that appears to play a critical role in glioblastoma growth and survival, while being largely absent from normal brain tissue. Specifically, the funded research will focus on advancing preclinical validation and lead optimization, with the goal of generating the data needed to support future clinical development. By emphasizing rigorous science and translational relevance, this work aligns closely with our mission to accelerate progress toward more effective treatments for patients and families affected by GBM.